

**No recommendation****Price 8p****Mining****United Kingdom**

AIM	703
Reuters/Bloomberg	JLP
No. of shares in issue (m)	313.2
Market Cap (£m)	25.1
Website	<a href="http://www.jubileeplatinum.com">www.jubileeplatinum.com</a>

# Jubilee Platinum<sup>+</sup>\*

## First 'own' concentrates in H2 FY2013

Jubilee Platinum released good news on November 21<sup>st</sup>, 2012, announcing that the processing of tailings and current arisings from the Dilokong Chrome Mine (DCM) should commence "shortly". Jubilee has effectively been granted exclusive access to the full capacity of Platinum Australia's nearby Smokey Hills concentrator for eight months. Meanwhile, a tailings treatment agreement formalising Jubilee's right to purchase platinum group elements (PGEs) in DCM's tailings and current arisings from Corridor Mining Resources (CMR) has been executed. These deals underline the importance of cash generation as a key differentiator separating Jubilee from its explorer-developer peers, in our opinion. We reiterate our belief that there is a strong case for a much higher valuation than currently attributed by the market.

**Platinum Australia (PLA) demise is Jubilee opportunity:** Jubilee's exclusivity period for full capacity access to the Smokey Hill concentrator (which the parties may jointly agree to extend) starts 30 days from November 8<sup>th</sup>, 2012. A toll processing agreement is being formalised. The concentrator access means Jubilee will be able to bring production of own PGE concentrates forward by 18 months for a minimal capital outlay. Jubilee intends to process up to 50ktpm of material, producing 1.7koz PGEs-in-concentrate/month at steady state.

**CMR agreement - PGEs in exchange for concentrate royalties:** Jubilee will pay CMR a percentage of concentrate sales revenues and an initial upfront fee of ZAR10m (c£0.714m). The upfront fee is off-settable from future revenue payments, and Jubilee can choose to pay said fee in cash or shares. There are also provisions relating to the construction and operation of a concentrator at DCM, should this be required.

**Jubilee keeps all smelting profits:** We expect the PGE concentrate to be "toll-smelted" at Jubilee's Middelburg facility, leveraging the company's exclusive ConRoast process and allowing it to keep all of the smelting profits. We note that Jubilee is the only junior PGM company able to smelt its own concentrate.

**More to come:** Interestingly, though not unexpectedly, Jubilee expects to "follow up other pending and new acquisitions in the new year for concentrate production".

**Valuation anomaly:** We have amended our Jubilee model for the above news; in addition, we have now incorporated the previously announced electricity sales and pushed out Tjate and the Sylvania joint venture by one year (Figures 1-3). Our present sum-of-the-parts NPV of 79p/share fully diluted remains significantly higher than the current share price. In our notes dated April 2<sup>nd</sup> and September 28<sup>th</sup>, 2012, we showed that peer average EV/oz values suggest at least c200% upside and that Jubilee has been one of the better performers in the PGM space. We reiterate our belief that the case for a much higher market valuation is strong.

**\*Shore Capital Stockbrokers Limited acts as joint broker to Jubilee Platinum.**

**Disclosures of potential conflicts of interest as required by regulatory bodies are shown on page 5**

**Research Analyst****Yuen Low**

yuen.low@shorecap.co.uk  
+44 (0) 207 647 8152

**Corporate Broking****Jerry Keen**

jerry.keen@shorecap.co.uk  
+44 (0) 207 468 7964

**+Conflicts of interest:**

The analyst who has prepared this report is aware that Shore Capital Stockbrokers and/or another member of the Shore Capital Group has a relationship with the company covered in this research report. Accordingly, Shore Capital may have a conflict of interest and this research report should be viewed as being non-objective. A copy of our policy for managing conflicts of interest can be found on our website at [www.shorecap.co.uk](http://www.shorecap.co.uk)

## Model revised

We have revised our Jubilee model to reflect the tailings retreatment developments and electricity sales, amongst other things

We have revised our Jubilee Platinum model as follows:

- We are modelling the DCM retreatment operations as commencing in Q3 FY2013. We assume that Jubilee will be able to process 50ktpm of dump material for approximately a year, and then current arisings at 15ktpm for a further 5 years.
- Our Braemore Platinum Smelters model has been amended to take into account the terms of the DCM retreatment operations.
- Electricity sales have been incorporate into our JSR model.
- The timelines in our Tjate and Volspruit models have been pushed out by one year; Leinster and Kambalda remain unchanged for the time being.
- We have updated our commodity price and exchange rate assumptions.

**Fig 1: Updated commodity price and exchange rate assumptions\***

MODEL ASSUMPTIONS		FY2011A	FY2012A	FY2013F	FY2014F
Platinum	US\$/oz	1,708	1,604	1,625	1,688
Palladium	US\$/oz	682	673	688	950
Rhodium	US\$/oz	2,292	1,567	1,242	1,800
Copper	US\$/t	8,663	8,171	8,681	10,472
ZAR/USD	ZAR/US\$	7.00	7.79	8.43	7.69
AUD/USD	A\$/US\$	1.01	0.97	0.98	1.00

\*Fiscal 30<sup>th</sup> June.

Source: Bloomberg, Shore Capital estimates

Our sum-of-the-parts DCF valuation for Jubilee is 79p/share; this valuation is most sensitive to metal prices and operating costs

Jubilee's current c8p/share is significantly below our sum-of-the-parts valuation

This share price is just 0.26x of Tjate's NPV, versus a typical range of 0.5-0.8x at other companies...

...despite Tjate comparing well with other projects

## Share price is much lower than DCF sum-of-the-parts

Our revised sum-of-the-parts DCF valuation for Jubilee Platinum is 79p/share (previously 80p/share). This valuation is most sensitive to metal prices and operating costs – a 10% increase in the dollar 5E+Au basket increases our valuation by 20.2%, whereas a 10% rise in operating costs decreases it by 27.2%. The rand exchange rate has a non-linear effect – depreciation boosts value less than appreciation reduces it.

Jubilee Platinum's shares are currently trading at c8p/share, just 10.1% of our sum-of-the-parts valuation. Even stripping out the Australian assets – which we regard as non-core – yields a significantly higher value: 64p/share.

In our experience, junior Platinum Group Metal (PGM) companies tend to trade on multiples in the region of 0.5-0.8x their flagship project's NPV. Yet, even on this basis, Jubilee Platinum is trading at just 0.17x of South African flagship project Tjate's NPV.

This is despite Tjate comparing very well with other projects in its key aspects (as discussed in our Initiation of Coverage note of October 21<sup>st</sup>, 2011) – before we even consider that Tjate's economics should be significantly enhanced by Jubilee Platinum's proprietary ConRoast smelting technology (which obviates the need to give up significant value to toll smelters) and CVMR<sup>®</sup> refining (which will significantly improve nickel payability).

Tjate's quality received a significant indirect endorsement when a PGM major offered to purchase the undrilled Quartzhill farm

It should be remembered that in October 2011, the high quality of Tjate's ground received a resounding, indirect endorsement when an unnamed PGM major offered to purchase Tjate's Quartzhill farm for ZAR75m (c£6m). If this sounds a small sum, it should be borne in mind that that sum is being offered for an undrilled property. Furthermore, the PGM resources at the Quartzhill farm (which is immediately down-dip of Anglo American Platinum's Twickenham mine) occur at significantly greater depths than at Tjate's 'first mine' area. We caution, therefore, that extrapolating a value for Tjate's 'first mine' from the Quartzhill sales price would significantly undervalue Tjate.


We estimate that the toll businesses are worth 19p/share

Meanwhile, the already cash-generative ferroalloys business and the PGM toll-processing business are in themselves worth 19p/share.

Jubilee Platinum is undervalued on any bases

In short, purely in terms of NPV, it is hard to avoid the conclusion that Jubilee Platinum is significantly undervalued. In our notes dated April 2<sup>nd</sup> and September 28<sup>th</sup>, 2012, we showed that peer average EV/oz values suggest at least c200% upside and that Jubilee has been one of the better performers in the PGM space. We reiterate our belief that the case for a much higher market valuation is strong.

**Fig 2: Sum-of-the-parts FY2013F DCF valuation**



\* We assume BHP exercises its 50% buy-in rights.

Source: Shore Capital estimates

Fig 3: Financial statements

Vital Statistics		FY2011A	FY2012A	FY2013F	FY2014F
EPS	p/share	(2.67)	(2.61)	(2.27)	(2.03)
P/E	x	n.m.	n.m.	n.m.	n.m.
CFPS	p/share	(2.70)	(1.75)	(1.21)	(0.75)
P/CFPS	x	n.m.	n.m.	n.m.	n.m.
Net Debt/(Cash)**	£m	(0.73)	1.10	15.97	124.78
Average Shares OS	m	255.84	279.15	303.48	318.83
Average Shares FD	m	265.61	288.92	333.74	346.62
INCOME STATEMENT		FY2011A	FY2012A	FY2013F	FY2014F
<b>Net Revenue</b>	<b>£m</b>	<b>5.50</b>	<b>3.73</b>	<b>8.25</b>	<b>14.52</b>
Operating Costs	£m	(9.51)	(10.19)	(11.98)	(16.40)
<b>EBITDA</b>	<b>£m</b>	<b>(4.01)</b>	<b>(6.46)</b>	<b>(3.73)</b>	<b>(1.88)</b>
Depreciation & Amortisation	£m	(2.50)	(1.84)	(2.56)	(2.77)
<b>EBIT</b>	<b>£m</b>	<b>(6.51)</b>	<b>(8.31)</b>	<b>(6.29)</b>	<b>(4.65)</b>
Finance Income	£m	(0.50)	(0.33)	(0.18)	(0.15)
<b>Pre-Tax Profit</b>	<b>£m</b>	<b>(7.01)</b>	<b>(8.64)</b>	<b>(6.46)</b>	<b>(4.80)</b>
Taxes	£m	(0.58)	0.26	(0.25)	(1.11)
Minorities	£m	0.77	1.09	(0.18)	(0.55)
<b>Attributable Net Income</b>	<b>£m</b>	<b>(6.82)</b>	<b>(7.29)</b>	<b>(6.90)</b>	<b>(6.46)</b>
<b>EPS</b>	<b>p/share</b>	<b>(2.67)</b>	<b>(2.61)</b>	<b>(2.27)</b>	<b>(2.03)</b>
BALANCE SHEET		FY2011A	FY2012A	FY2013F	FY2014F
Cash & Equivalents	£m	2.01	1.06	(13.80)	(122.61)
Other Current Assets	£m	3.95	1.67	2.40	3.46
<b>Current Assets</b>	<b>£m</b>	<b>5.96</b>	<b>2.73</b>	<b>(11.40)</b>	<b>(119.15)</b>
PP&E	£m	103.58	93.80	104.37	207.78
Other	£m	0.52	0.00	0.00	0.00
<b>Total Assets</b>	<b>£m</b>	<b>110.06</b>	<b>96.53</b>	<b>92.97</b>	<b>88.62</b>
Short-term Debt	£m	1.28	2.16	2.16	2.16
Other Current Liabilities	£m	4.18	3.08	3.51	4.51
<b>Current Liabilities</b>	<b>£m</b>	<b>5.46</b>	<b>5.25</b>	<b>5.67</b>	<b>6.68</b>
Long Term Debt	£m	0.00	0.00	0.00	0.00
Other Long Term Liabilities	£m	15.28	13.42	12.74	11.49
<b>Total Liabilities</b>	<b>£m</b>	<b>20.744</b>	<b>18.666</b>	<b>18.4156</b>	<b>18.1652</b>
Shareholder Equity	£m	60.16	64.42	66.63	66.63
Retained Income	£m	(21.06)	(28.35)	(35.25)	(41.70)
Other	£m	50.21	41.78	43.17	45.53
<b>Total Liabilities &amp; Equity</b>	<b>£m</b>	<b>110.06</b>	<b>96.53</b>	<b>92.97</b>	<b>88.62</b>
CASHFLOW STATEMENT		FY2011A	FY2012A	FY2013F	FY2014F
Net Income	£m	(6.82)	(7.29)	(6.90)	(6.46)
DD&A	£m	2.50	1.32	2.56	2.77
Other	£m	(10.09)	(0.10)	0.96	1.36
Change in Working Capital	£m	7.51	1.18	(0.30)	(0.06)
<b>Cash Flow from Operations</b>	<b>£m</b>	<b>(6.91)</b>	<b>(4.89)</b>	<b>(3.68)</b>	<b>(2.39)</b>
Capital Expenditure	£m	(3.76)	(0.79)	(18.24)	(106.17)
Other	£m	1.07	0.00	5.58	0.00
<b>Cash Flow from Investments</b>	<b>£m</b>	<b>(2.68)</b>	<b>(0.79)</b>	<b>(12.66)</b>	<b>(106.17)</b>
Equity Issues (Net of Costs)	£m	0.00	4.42	1.73	0.00
Net Borrowings	£m	0.00	0.00	0.00	0.00
Other	£m	(1.64)	(0.52)	(0.25)	(0.25)
<b>Cash Flow from Financing</b>	<b>£m</b>	<b>(1.64)</b>	<b>3.90</b>	<b>1.47</b>	<b>(0.25)</b>
<b>Net Cashflow</b>	<b>£m</b>	<b>(11.23)</b>	<b>(1.78)</b>	<b>(14.87)</b>	<b>(108.81)</b>
FX Adjustments	£m	0.16	0.24	0.83	0.00
<b>Cash at End of Year</b>	<b>£m</b>	<b>2.01</b>	<b>1.06</b>	<b>(13.80)</b>	<b>(122.61)</b>

\* All GBP unless otherwise noted; fiscal year-end 30<sup>th</sup> June.

\*\* FY2013 and FY2014 net debt reflects funding requirements, which could be met from equity and/or debt.

Source: Jubilee Platinum, Shore Capital estimates

## CONFLICTS

### + Non-Independent Marketing Communication:

This is a non-independent marketing communication. The analyst who has prepared this report is aware that Shore Capital Stockbrokers Limited and/or another member of Shore Capital has a relationship with the company covered in this report. Accordingly it has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on the dealing ahead of the dissemination of investment research.

## DISCLOSURES

It is the policy of Shore Capital Stockbrokers Limited not to make recommendations on companies for which it acts in an advisory capacity.

Research recommendations:

Stock recommendation definitions:

Buy 10%+ absolute performance within 3-months or otherwise as specified

Hold +/- 10% absolute performance on a 3-month basis or otherwise as specified

Sell -10% absolute performance on a 3-month basis or otherwise as specified

Research distribution:

In the period 2<sup>nd</sup> July 2012 to 28<sup>th</sup> September 2012, Shore Capital Stockbrokers covered 155 'non-house' stocks. There was a Buy recommendation on 80 (52%) stocks, a Hold recommendation on 58 (37%) stocks, a Sell recommendation on 17 (11%) stocks and a total number of 155 (100%). The breakdown above only applies to 'non-house' stocks.

Lead analyst:

The lead analyst with respect to each research item is the first and most prominent name. Please note that more than one analyst may work on a specific research item.

Recommendation history:

For details of recommendation history on a specific stock please contact your Shore Capital contact on 020 7408 4080/0151 600 3700. All formal research notes carry specific recommendation history information.

The information above is obtained from sources considered reliable. However, the accuracy thereof cannot be guaranteed by us. Shore Capital or any of its associated companies (or our or their employees) may from time to time hold positions in the above equities as principal, and may also perform corporate advisory services for these companies. The suitability of any investment recommendations for private investors will depend upon their circumstances and they should therefore discuss the recommendations with our dealers before investing. Share prices can go down as well as up and past performance is not necessarily a guide to the future. Some investments may require you to pay more money than the cost of the investment. Levels and bases of taxation may change.

This document is being supplied to you solely for your information and may not be reproduced or further distributed to any person (including the media) or published in whole or in part, for any purpose. The material in this document is not intended for distribution or use outside the European Economic Area or Switzerland. This material is not directed at you if Shore Capital is prohibited or restricted by any legislation or regulation in any jurisdiction from making it available to you. All relationships giving rise to a conflict of interest as defined under the Conduct of Business rules of the Financial Services Authority have been disclosed. The issue of this note is not necessarily indicative of long term coverage of the stock. Hence, updates may or may not be issued in the future.

The views expressed in this document accurately reflect the research analyst's personal views about any and all of the subject securities and the Company on the date of this document. Any opinion or estimate expressed in this document is subject to change without notice. Shore Capital may act upon or use the information or a conclusion contained in this document before it is distributed to other persons. This document is published solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. None of Shore Capital Stockbrokers Limited or any member of Shore Capital, or any of its or their directors, officers, employees or agents accept any responsibility or liability whatsoever for any loss however arising from any use of this document or its contents or otherwise arising in connection therewith. By accepting this document, you agree to be bound by the foregoing limitations.

The following applies if the company is quoted on "AIM" – defined as the AIM Market of the London Stock Exchange. AIM is a market designed primarily for emerging or smaller companies and the rules of this market are less demanding than those of the Official List of the UKLA, consequently AIM investments may not be suitable for some investors. Liquidity may be lower and hence some investments may be harder to realise.

**SHORE CAPITAL STOCKBROKERS LIMITED**  
MEMBER OF THE LONDON STOCK EXCHANGE  
AUTHORISED AND REGULATED BY THE FINANCIAL SERVICES AUTHORITY

©2012 Shore Capital Stockbrokers Limited



## Contacts

All Shore Capital contacts can be emailed as follows: [firstname.lastname@shorecap.co.uk](mailto:firstname.lastname@shorecap.co.uk)

### Analysts

<b>Clive Black</b> <i>Food &amp; Drug Retailers, Food Producers, Household &amp; Personal Goods</i>	+44 (0)151 600 3701
<b>Darren Shirley</b> <i>Food &amp; Drug Retailers, Food Producers, Household &amp; Personal Goods</i>	+44 (0)151 600 3702
<b>Phil Carroll</b> <i>Beverages, Foodstuffs &amp; Tobacco</i>	+44 (0)151 600 3711
<b>Eamonn Flanagan</b> <i>Insurance, Life Assurance &amp; Lloyd's Vehicles</i>	+44 (0)151 600 3714
<b>Owen Jones</b> <i>Financial General</i>	+44 (0)151 600 3713
<b>Gary Greenwood</b> <i>UK Banks &amp; Speciality Lenders</i>	+44 (0)151 600 3717
<b>Robin Speakman</b> <i>Support Services &amp; Technology</i>	+44 (0)151 600 3712
<b>David O'Brien</b> <i>Recruitment &amp; Smaller Companies</i>	+44 (0)151 600 3707
<b>Gerard Lane</b> <i>Equity Strategy &amp; Economics</i>	+44 (0)151 600 3724
<b>Alex Stewart</b> <i>Equity Income Sales</i>	+44 (0)207 647 8156

<b>Jon Bell</b> <i>Property, Construction &amp; Building Materials</i>	+44 (0)207 647 8130
<b>Gavin Jago</b> <i>Property, Construction &amp; Building Materials</i>	+44 (0)207 647 8121
<b>Greg Johnson</b> <i>Travel &amp; Leisure</i>	+44 (0)151 600 3704
<b>Karl Burns</b> <i>Travel &amp; Leisure</i>	+44 (0)151 600 3720
<b>Brian White</b> <i>Pharmaceuticals, Healthcare &amp; Medical Devices</i>	+44 (0)207 079 1671
<b>Paul Taylor</b> <i>Pharmaceuticals, Healthcare &amp; Medical Devices</i>	+44 (0)207 079 1675
<b>Craig Howie</b> <i>Oil &amp; Gas</i>	+44 (0)151 600 3703
<b>Yuen Low</b> <i>Small &amp; Mid Cap Mining</i>	+44 (0)207 647 8152

### Sales

<b>Rupert Armitage</b>	+44 (0)207 647 8123
<b>Richard Arthur</b>	+44 (0)151 600 3706
<b>Andy Forshaw</b>	+44 (0)151 600 3708
<b>Stephen Henney</b>	+44 (0)151 600 3718
<b>Jane Hodgson</b>	+44 (0)151 600 3715
<b>David Izzard</b>	+44 (0)207 647 8163
<b>Andrew Keith</b>	+44 (0)207 079 1672

<b>Philip Kerr</b>	+44 (0)207 647 8178
<b>Malachy McEntyre</b>	+44 (0)151 600 3710
<b>John Ritchie</b>	+44 (0)151 600 3705
<b>Elliot Shaw</b>	+44 (0)207 647 8127
<b>Richard Sloss</b>	+44 (0)207 079 1673
<b>William De La Warr</b>	+44 (0)207 468 7933

### Sales Traders

<b>Simon Fine</b>	+44 (0)207 647 8133
<b>Barrie Ashton</b>	+44 (0)207 647 8124
<b>Russell Brody</b>	+44 (0)207 647 8120

<b>Will Porter</b>	+44 (0)207 647 8132
<b>David Simmons</b>	+44 (0)207 647 8126
<b>Simon Thomas</b>	+44 (0)207 647 8145

### Corporate Broking

<b>Dru Danford</b>	+44 (0)207 468 7905
<b>Stephane Auton</b>	+44 (0)207 408 4062
<b>Nick Bankes</b>	+44 (0)151 600 3700
<b>Bidhi Bhoma</b>	+44 (0)207 468 7904
<b>Patrick Castle</b>	+44 (0)207 468 7923

<b>Anita Ghanekar</b>	+44 (0)207 408 4052
<b>Toby Gibbs</b>	+44 (0)207 468 7967
<b>Pascal Keane</b>	+44 (0)207 468 7995
<b>Jerry Keen</b>	+44 (0)207 468 7964
<b>Edward Mansfield</b>	+44 (0)207 468 7906

### London Office

Bond Street House  
14 Clifford Street  
London W1S 4JU  
T: +44 (0)207 408 4080

### Liverpool Office

The Corn Exchange  
Fenwick Street  
Liverpool L2 7RB  
T: +44 (0)151 600 3700

### Edinburgh Office

1<sup>st</sup> Floor  
3/5 Melville Street  
Edinburgh EH3 7PE  
T: +44 (0)207 079 1670